# US 2024/0189355 A1 · Hypoimmunogenic cells having targeted modifications in mhc class-i genes and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189355 A1
- Document ID: US20240189355A1
- Status: Published application
- Kind: A1
- Application number: 18/509,110
- Filed: 2023-11-14
- Published: 2024-06-13
- Earliest claimed: 2022-11-14
- Applicants: Wugen, Inc.
- Inventors: You ZHOU; Matthew COOPER; Elizabeth SCHRAMM
- Web page: https://patentgrep.com/patent/US20240189355A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- C12N 5/06: {Animal cells or tissues; Human cells or tissues (preservation of excised living parts A01N1/10)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/421: {Immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 2239/15: Non-antibody based
- A61K 2239/30: Mixture of cells
- C12N 2310/17: Immunomodulatory nucleic acids
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2506/11: from blood or immune system cells
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides compositions of genetically modified cells that are hypoimmunogenic. The present disclosure also provides methods of making hypoimmunogenic cells and using hypoimmunogenic cells for the treatment of cancer and autoimmune conditions.

## Claims

### Claim 1

An hypoimmunogenic cell comprising one or more genetic modifications in one or more HLA genes selected from the group consisting of: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G, wherein the modification (i) reduces or prevents a CD8+ T cell-mediated response against the hypoimmunogenic cell, and/or (ii) reduces or prevents an NK cell-mediated response against the hypoimmunogenic cell.

### Claim 2 (depends on 1)

The hypoimmunogenic cell of claim 1, wherein the one or more genetic modifications comprises a modification in one or more domains of the one or more HLA genes selected from the group consisting of: alpha 1 domain, alpha 2 domain, alpha 3 domain, transmembrane domain, intracellular domain, and signal peptide region.

### Claim 3 (depends on 1)

The hypoimmunogenic cell of claim 1, wherein the one or more genetic modifications comprises a modification in the alpha 3 domain of the one or more HLA genes.

### Claim 4 (depends on 1)

The hypoimmunogenic cell of claim 1, wherein the one or more genetic modifications encode one or more single amino acid substitutions.

### Claim 5 (depends on 2)

The hypoimmunogenic cell of claim 2, wherein the one or more genetic modifications encode one or more modifications at one or more amino acid residues selected from the group consisting of: A245, D227, T228, K66, and R65.

### Claim 6 (depends on 2)

The hypoimmunogenic cell of claim 2, wherein the one or more genetic modifications encode one or more amino acid substitutions selected from the group consisting of: A245V, D227K, T228A, K66A, and R65A.

### Claim 7 (depends on 1)

The hypoimmunogenic cell of claim 1, wherein the one or more genetic modifications encode a modification at A245 in HLA-A, HLA-B, and HLA-C.

### Claim 8 (depends on 7)

The hypoimmunogenic cell of claim 7, wherein the modification is A245V.

### Claim 9 (depends on 1)

The hypoimmunogenic cell of claim 1, wherein the one or more genetic modifications encode a modification at D227 in HLA-A, HLA-B, and HLA-C and a modification at T228 in HLA-A, HLA-B, and HLA-C.

### Claim 10 (depends on 9)

The hypoimmunogenic cell of claim 9, wherein the modification at D227 is D227K and the modification at T228 is T228A.

### Claim 11 (depends on 1)

The hypoimmunogenic cell of claim 1, wherein the one or more genetic modifications comprises one or more in-frame stop codon mutations.

### Claim 12 (depends on 11)

The hypoimmunogenic cell of claim 11, wherein the hypoimmunogenic cell comprises one or more exogenously expressed HLA genes, optionally wherein the HLA genes comprise one or more mutations.

### Claim 13 (depends on 12)

The hypoimmunogenic cell of claim 12, wherein the hypoimmunogenic cell comprises an exogenously expressed HLA-E gene.

### Claim 14 (depends on 1)

The hypoimmunogenic cell of claim 1, wherein the genetic modification is introduced using a gene editing technique, optionally wherein the gene editing technique is selected from the group consisting of CRISPR-Cas9 gene editing, prime editing, and base editing.

### Claim 15 (depends on 1)

The hypoimmunogenic cell of claim 1, wherein the hypoimmunogenic cell is differentiated or derived from a stem cell, optionally wherein the stem cell is an induced pluripotent stem cell (iPSC).

### Claim 16 (depends on 1)

The hypoimmunogenic cell of claim 1, wherein the hypoimmunogenic cell is an immune cell.

### Claim 17 (depends on 16)

The hypoimmunogenic cell of claim 16, wherein the hypoimmunogenic cell is selected from the group consisting of: a T cell, a B cell, an NK cell, a dendritic cell, and a macrophage.

### Claim 18 (depends on 1)

The hypoimmunogenic cell of claim 1, wherein the hypoimmunogenic cell further comprises a polynucleotide encoding a cell surface receptor, optionally wherein the cell surface receptor is a chimeric receptor.

### Claim 19

A method of making a hypoimmunogenic cell, the method comprising introducing into a cell one or more genetic modifications in one or more HLA genes selected from the group consisting of: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G; wherein the modification (i) reduces or prevents a CD8+ T cell-mediated response against the hypoimmunogenic cell, and/or (ii) reduces or prevents an NK cell-mediated response against the hypoimmunogenic cell.

### Claim at position 20

-40. (canceled)

### Claim 41 (depends on 1)

A pharmaceutical composition comprising the hypoimmunogenic cell of claim 1.

### Claim 42 (depends on 41)

A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 41.

### Claim at position 23

-44. (canceled)
